Drugs / DAA-I
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02666196 | Sep → Dec 2015 | — | National University Hospital, Singapore | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAA-I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02666196 ↗ |
| Action | Activate | “prototype angiotensin receptor agonist (ARA)” PMID 27681888 ↗ Dec 2016 |
| Modality | Peptide | “DAA-I is an endogenous angiotensin peptide” PMID 27681888 ↗ Dec 2016 |
| Route | Oral | “Orally Administered DAA-I” NCT02666196 ↗ |